Paradigm Biopharmaceuticals Limited (PBIGF)
USD 0.13
(-62.83%)
USD 0.13
(-62.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -58.65 Million AUD | -12.99% |
| 2023 | -51.91 Million AUD | -32.26% |
| 2022 | -39.24 Million AUD | -14.44% |
| 2021 | -34.29 Million AUD | -178.86% |
| 2020 | -12.29 Million AUD | 21.3% |
| 2019 | -15.62 Million AUD | -152.45% |
| 2018 | -6.19 Million AUD | -44.79% |
| 2017 | -4.27 Million AUD | -46.2% |
| 2016 | -2.92 Million AUD | -86.83% |
| 2015 | -1.56 Million AUD | -576.34% |
| 2014 | -231.43 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -4.84 Million AUD | 90.1% |
| 2024 Q2 | -48.95 Million AUD | -100.0% |
| 2024 Q1 | -24.47 Million AUD | -22.14% |
| 2024 Q4 | -4.84 Million AUD | 0.0% |
| 2024 FY | -58.65 Million AUD | -12.99% |
| 2023 Q2 | -31.86 Million AUD | -100.0% |
| 2023 Q4 | -20.04 Million AUD | -100.0% |
| 2023 Q1 | -15.93 Million AUD | -29.92% |
| 2023 FY | -51.91 Million AUD | -32.26% |
| 2023 Q3 | -10.02 Million AUD | 68.55% |
| 2022 Q2 | -26.98 Million AUD | -100.0% |
| 2022 Q4 | -12.26 Million AUD | -100.0% |
| 2022 FY | -39.24 Million AUD | -14.44% |
| 2022 Q3 | -6.13 Million AUD | 77.28% |
| 2022 Q1 | -13.49 Million AUD | 0.55% |
| 2021 Q4 | -13.56 Million AUD | -100.0% |
| 2021 FY | -34.29 Million AUD | -178.86% |
| 2021 Q1 | -10.36 Million AUD | -44.06% |
| 2021 Q2 | -20.73 Million AUD | -100.0% |
| 2021 Q3 | -6.78 Million AUD | 67.28% |
| 2020 Q3 | -3.59 Million AUD | 29.52% |
| 2020 FY | -12.29 Million AUD | 21.3% |
| 2020 Q2 | -5.1 Million AUD | -100.0% |
| 2020 Q1 | -2.55 Million AUD | 77.27% |
| 2020 Q4 | -7.19 Million AUD | -100.0% |
| 2019 Q4 | -11.22 Million AUD | -100.0% |
| 2019 Q1 | -2.2 Million AUD | -68.14% |
| 2019 Q2 | -2.2 Million AUD | 0.0% |
| 2019 Q3 | -5.61 Million AUD | -155.15% |
| 2019 FY | -15.62 Million AUD | -152.45% |
| 2018 Q3 | -1.3 Million AUD | 26.76% |
| 2018 FY | -6.19 Million AUD | -44.79% |
| 2018 Q4 | -1.3 Million AUD | 0.0% |
| 2018 Q2 | -1.78 Million AUD | 0.0% |
| 2018 Q1 | -1.78 Million AUD | -145.24% |
| 2017 Q3 | -728.51 Thousand AUD | 48.3% |
| 2017 Q2 | -1.4 Million AUD | 0.0% |
| 2017 Q1 | -1.4 Million AUD | -87.66% |
| 2017 FY | -4.27 Million AUD | -46.2% |
| 2017 Q4 | -728.51 Thousand AUD | 0.0% |
| 2016 Q1 | -711.27 Thousand AUD | 3.21% |
| 2016 Q3 | -750.93 Thousand AUD | -5.58% |
| 2016 Q4 | -750.93 Thousand AUD | 0.0% |
| 2016 FY | -2.92 Million AUD | -86.83% |
| 2016 Q2 | -711.27 Thousand AUD | 0.0% |
| 2015 Q2 | -302.66 Thousand AUD | 0.0% |
| 2015 Q4 | -734.85 Thousand AUD | 0.0% |
| 2015 FY | -1.56 Million AUD | -576.34% |
| 2015 Q1 | -302.66 Thousand AUD | 0.0% |
| 2014 FY | -231.43 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | -1435.826% |
| Skye Bioscience, Inc. | -37.64 Million USD | -55.807% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 190.052% |
| Nascent Biotech, Inc. | -2.08 Million USD | -2709.489% |
| Qrons Inc. | -789.34 Thousand USD | -7330.596% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -14017.004% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -739.962% |
| BioStem Technologies, Inc. | -8.48 Million USD | -591.422% |
| Regen BioPharma, Inc. | 1.02 Million USD | 5830.604% |
| CSL Limited | 2.64 Billion USD | 102.22% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 6.303% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 210.71% |
| Rebus Holdings, Inc. | -1.02 Million USD | -5650.313% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -4292.079% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -9174.595% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -269.552% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 21.757% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -791.913% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -21353.094% |
| SQZ Biotechnologies Company | -79.46 Million USD | 26.189% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -1927.842% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -3121.768% |
| Mesoblast Limited | -87.95 Million USD | 33.315% |
| Marizyme, Inc. | -65.34 Million USD | 10.243% |
| Genus plc | 7.9 Million USD | 842.445% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -438.511% |
| Pharming Group N.V. | -10.54 Million USD | -456.06% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -2603.144% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -1480.849% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -563.198% |
| ContraFect Corporation | -65.15 Million USD | 9.976% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -1100.418% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -3295.353% |
| IMV Inc. | -36.48 Million USD | -60.757% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -627.736% |
| MultiCell Technologies, Inc. | -380.07 USD | -15432106.699% |
| ONE Bio Corp. | 8.67 Million USD | 775.992% |
| Accustem Sciences Inc. | -3.74 Million USD | -1465.58% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -13.467% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -4528.807% |
| Q BioMed Inc. | -2.05 Million USD | -2758.213% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -1471.208% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -2363.519% |
| Biomind Labs Inc. | -1.21 Million USD | -4730.13% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 1.795% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -1790.96% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -642.155% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -2909.015% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -391547.89% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -908.263% |
| GB Sciences, Inc. | -1.36 Million USD | -4207.423% |
| Alpha Cognition Inc. | -13.77 Million USD | -325.87% |
| HST Global, Inc. | -146.21 Thousand USD | -40015.716% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -3242.498% |
| Halberd Corporation | -79.67 Thousand USD | -73514.624% |
| Enzolytics Inc. | -2.17 Million USD | -2594.429% |
| Agentix Corp. | -1.37 Million USD | -4168.136% |
| Resverlogix Corp. | -3.61 Million USD | -1524.742% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -1749.421% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 80.121% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 59950.192% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 947.027% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -1376.297% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -1838.221% |
| AVAX Technologies, Inc. | -6.41 Million USD | -814.506% |
| Zenith Capital Corp. | -10.59 Million USD | -453.541% |
| Genscript Biotech Corporation | -95.47 Million USD | 38.568% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -252258.609% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -1314.715% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -96942.68% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -2825.178% |
| Kadimastem Ltd | -3.3 Million USD | -1673.394% |
| Helix BioMedix, Inc. | -1.05 Million USD | -5453.979% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -13188.923% |
| LadRx Corporation | 400.44 Thousand USD | 14747.075% |
| Cell Source, Inc. | -5.32 Million USD | -1002.252% |
| Regen BioPharma, Inc. | 1.02 Million USD | 5830.604% |
| NovAccess Global Inc. | -4.76 Million USD | -1129.836% |
| Affymax, Inc. | -14.42 Million USD | -306.636% |
| Itoco Inc. | -1.86 Million USD | -3038.221% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -1220.264% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -3414.271% |
| Mobile Lads Corp. | -2.26 Million USD | -2491.499% |
| CytoDyn Inc. | -49.84 Million USD | -17.681% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -74113.541% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -25610.761% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -6129.568% |
| SYBLEU INC | -180.3 Thousand USD | -32430.165% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -3536.872% |
| International Stem Cell Corporation | -131 Thousand USD | -44673.426% |
| Bioxytran, Inc. | -4.28 Million USD | -1270.401% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -107972.649% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -2218.082% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -22.011% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -2674.512% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -7411.098% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -1751.426% |
| Neutra Corp. | -233.46 Thousand USD | -25022.904% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -189.06% |
| PureTech Health plc | -65.69 Million USD | 10.722% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -175.8% |
| IXICO plc | -1.17 Million USD | -4879.048% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -490.845% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -2.67% |
| CSL Limited | 2.64 Billion USD | 102.22% |
| Cellectis S.A. | -103.17 Million USD | 43.151% |